• Our Partners
  • CarePolicy
  • HomeCareConsulting
  • Digit9X
  • Home
  • Assisted Living
  • Elderly
  • Home Care Agency
  • Home Care Worker
  • Home Nursing
Menu
  • Home
  • Assisted Living
  • Elderly
  • Home Care Agency
  • Home Care Worker
  • Home Nursing
Home » Tariff threats and drug prices will be two key issues for the pharmaceutical industry in Trump's first year
Elderly

Tariff threats and drug prices will be two key issues for the pharmaceutical industry in Trump's first year

adminBy adminJuly 1, 2007No Comments4 Mins Read
Facebook Twitter Pinterest Telegram LinkedIn Tumblr Email Reddit
Share
Facebook Twitter LinkedIn Pinterest Email Copy Link


Like many industries preparing for Donald Trump's second term in office, the outlook for healthcare is mixed.

However, headwinds such as tariffs and drug pricing are clearly blowing strongly. Analysts on the sidelines are also taking a wait-and-see approach.

“Uncertainty surrounding policy changes is holding investors back, but potential administrative reforms under President Trump and related candidates are expected to continue in 2025,” analysts at Leerink Partners said in a December note. “We believe there will be more clarity through the appointment process early in the year.”

The three key issues being watched are China, tariffs, and drug prices.

China is an important market for the pharmaceutical industry for two reasons.

First, it is a source of revenue and global competition. Big pharma companies like Merck (MRK), Johnson & Johnson (JNJ), and AstraZeneca (AZN) have a significant presence there. It is also a major source of active pharmaceutical ingredients (APIs), the building blocks used in therapeutics and biopharmaceuticals.

NYSE – Delayed Estimates • USD

Ends: January 17th 4:00:25pm EST

M.R.K. JNJ AZN

In its third-quarter earnings report in October, Mizuho noted, for example, that J&J is the largest player in China's medical technology market, from which it derives 5% of its revenue. Meanwhile, China is growing in the global pharmaceutical market, accounting for 12% of the global market in 2021, second only to the United States with 40%.

China's exports to the United States have also increased, not decreased, since the pandemic. Since 2020, U.S. imports have increased by 485%, from $2.1 billion in 2020 to $10.3 billion in 2023.

Analysts at Jefferies say billions of dollars are at stake as Trump's pro-business reputation could collide with Congress' efforts to pass biosecure legislation. The bill would prohibit companies receiving federal funds, such as research grants, from engaging with Chinese companies. This includes purchasing APIs, creating demand for new partners, etc. According to the FDA, China currently accounts for 13% of the world's API manufacturers.

On September 13, 2024, a worker manufactures diclofenac sodium injection at a pharmaceutical company in Suqian, China. (Photo: Costfoto/NurPhoto, Getty Images)
A worker manufacturing diclofenac sodium injection at a pharmaceutical company in Suqian, China, on September 13, 2024. (Photo: Costfoto/NurPhoto, Getty Images) · NurPhoto (from Getty Images)

“Reducing drug prices is an area of ​​focus for both Republicans and Democrats, and Chinese CDMOs (manufacturers) such as Wuxi Group play a key role in reducing costs for U.S. drug companies by 30 to 60 percent. Trump “The administration is also likely to further reduce its business-friendliness and pressure from U.S. pharmaceutical companies on the BioSecure Act, making it unlikely that the law will be reinstated next year,” the analysts wrote. .

The tariffs could also have a negative impact on the medical technology sector, increasing the prices of medical supplies and equipment as well as the costs of related surgeries and other medical procedures, leading to higher insurance premiums. There is a possibility that

story continues

Experts believe medical supplies and equipment could be exempted from the tariffs.

Drug pricing is the last major issue facing the healthcare sector in 2025, but analysts don't expect it to actually be resolved until 2027.

The Biden administration's implementation of Medicare drug price negotiations under the Inflation Control Act could set a roadmap for more aggressive negotiations in the future, but next year's prices have already been set or are currently being negotiated. It is.

Meanwhile, President Trump may reconsider lowering overall drug costs by raising the prices other countries pay. But it could be a tough battle.

“For example, we will wait to see if President Trump criticizes U.S. drug prices in his State of the Union address and whether officials attack drug prices,” Leerink Partners analyst David Reisinger wrote in a note last month. There is a need.”

He added, “It is also possible that the Trump administration is seeking to lower Medicare Part D drug prices through 'tougher' IRA negotiations, so keep an eye out for future updates to the IRA Price Negotiation Guidance Document.”

Anjalee Khemlani is a senior health reporter at Yahoo Finance, covering all areas of pharma, insurance, care services, digital health, PBM, and health policy and politics. Of course, this also includes GLP-1. Follow Anjalee on social media platform X (Twitter) and LinkedIn Bluesky @AnjKhem.

Click here for a detailed analysis of the latest healthcare industry news and events impacting stock prices.



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
admin
  • Website

Related Posts

2025 Global Healthcare Outlook

June 23, 2025

Supplements that are wary of severe drug-induced liver injuries in the United States

May 21, 2025

Why people who eat high protein should eat more fiber

May 21, 2025
Leave A Reply Cancel Reply

Top Posts

2025 Global Healthcare Outlook

June 23, 2025

Understand Latin health at Adelantando Healthcare Conference

January 1, 1970

Seton Hall's new university university program explores women's healthcare for future health leaders

January 1, 1970

North Texas medical chain faces possible $300 million fine for 20,000 fake Medicare claims

January 28, 2003
Don't Miss

Streeting announces national investigation into maternity

By adminJune 23, 2025

A national investigation into NHS maternity services in England has been launched by health and…

Assisted dying bill voted through the House of Commons

June 20, 2025

Two Leeds maternity units rated ‘inadequate’ amid safety concerns

June 20, 2025

NMC warned against ‘performative change’ amid new criticism

June 20, 2025

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

About Us
About Us

Welcome to HomeCareNews.us, your trusted source for comprehensive information on home healthcare services. Our mission is to empower individuals and families by providing accurate, up-to-date, and insightful information about essential home care services in USA.

Facebook X (Twitter) Pinterest YouTube WhatsApp
Our Picks

2025 Global Healthcare Outlook

June 23, 2025

Streeting announces national investigation into maternity

June 23, 2025

When caregivers are gone: The hidden crisis of aging services

June 23, 2025
Most Popular

2025 Global Healthcare Outlook

June 23, 2025

Understand Latin health at Adelantando Healthcare Conference

January 1, 1970

Seton Hall's new university university program explores women's healthcare for future health leaders

January 1, 1970
  • Home
  • About Us
  • Advertise with Us
  • Contact us
  • DMCA Policy
  • Privacy Policy
  • Terms & Conditions
© 2025 HomecareNews.US

Type above and press Enter to search. Press Esc to cancel.